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Although cellular therapies hold great promise for the treatment of human disease, results from several initial
clinical trials have not shown a level of efficacy required for their use as a first line therapy. Here we discuss
how in vivo molecular imaging has helped identify barriers to clinical translation and potential strategies that
may contribute to successful transplantation and improved outcomes, with a focus on cardiovascular and
neurological diseases. We conclude with a perspective on the future role of molecular imaging in defining
safety and efficacy for clinical implementation of stem cell therapies.Introduction: Basics of Molecular Imaging
Stem cell therapies provide unique opportunities for treating dis-
eases of the heart and brain, which have limited regenerative
capacity. Because somatic stem cells from the heart and brain
are rare and difficult to isolate, therapeutic approaches using
adult stem cells and differentiated cells derived from pluripotent
stem cells provide a promising alternative source for regenerat-
ing cardiac and brain tissue (Garbern and Lee, 2013; Yu et al.,
2013). Successful implementation of cell therapies will require
a better understanding of cell fate after transplantation, which
can be achieved by the application of molecular imaging. Molec-
ular imaging enables the longitudinal, noninvasive assessment of
cellular behavior in vivo following cell transplantation (Massoud
and Gambhir, 2003). Cell tracking can be performed by labeling
cells with molecular probes that enter the cell by active/passive
transport and are trapped intracellularly (e.g., direct labeling).
Alternatively, cells can be labeled by overexpression of specific
reporter genes that integrate into the cellular genome via viral or
nonviral vectors (e.g., reporter gene labeling) (Figure 1). Once in-
tegrated, reporter genes are transcribed into messenger RNA
and translated into proteins that interact with a molecular probe
for signal generation. Although reporter gene imaging requires
genomic manipulation and poses potential safety issues, it is
the preferred labeling strategy because signal generation is
dependent on cell viability. Signal generated from cells labeled
by either technique can then be visualized using imaging
systems such as fluorescence imaging (FLI), bioluminescence
imaging (BLI), single-photon emission computed tomography
(SPECT), positron emission tomography (PET), or magnetic
resonance imaging (MRI). The advantages and disadvantages
of each imaging system are summarized in Table 1 and can be
found in other detailed reviews (Chen and Wu, 2011; Nguyen
et al., 2011).
Akin to the use of pharmacokinetics for drug development, the
overall goal of molecular imaging in regenerative medicine is to
enhance therapeutic efficacy and decrease toxicity. Results
from preclinical and clinical studies thus far suggest that cell
imaging can and should be incorporated into more studies of
cell transplantation in animals and humans. Continued applica-
tion of molecular imaging for regenerative cell therapies will becritical for its successful implementation. In this Review, we will
discuss how stem cell imaging has helped identify the hurdles
currently limiting the clinical translation of regenerative cell ther-
apies for cardiovascular and neurological diseases, how it can
be applied to define strategies to overcome these obstacles,
and how it can be incorporated in the clinical implementation
of regenerative stem cell therapies.
Defining Hurdles to Clinical Translation: Findings from
Preclinical and Clinical Studies
Small and large animal studies have shown that stem cell thera-
pies are effective in treating cardiovascular disease (van der
Spoel et al., 2011) and neurodegenerative disease (Antonic
et al., 2013; Lees et al., 2012). Based on these promising results,
investigators have launched several phase I and II studies to
evaluate the safety and efficacy of stem cell therapies for the
treatment of ischemic heart disease (Bolli et al., 2011; Hare
et al., 2012; Heldman et al., 2014; Perin et al., 2012; Traverse
et al., 2011, 2012), peripheral vascular disease (Poole et al.,
2013), spinal cord injury (Mothe and Tator, 2012), multiple scle-
rosis (Uccelli et al., 2011), and stroke (Bang et al., 2005; Kond-
ziolka et al., 2005; Lee et al., 2010). While safety has been clearly
demonstrated, efficacy remains more elusive (Clifford et al.,
2012; Fadini et al., 2010;Mothe and Tator, 2012). Based on these
results, one may conclude that cell therapy itself may be inade-
quate or that better results could be achieved with different cell
types. It is also possible that we have yet to apply these novel
therapies effectively. Indeed, findings from current trials under-
score the need to better understand the fate of transplanted cells
and their correlation with structural outcome (i.e., infarct size and
left ventricular volume at end diastole) and functional outcome
(i.e., left ventricular ejection fraction [LVEF] and neurocognitive
and motor function) (Bang et al., 2005; Bolli et al., 2011; Kond-
ziolka et al., 2005;Makkar et al., 2012; Perin et al., 2012; Traverse
et al., 2011, 2012).
The efficacy of any cell therapy depends on the interaction of
many different factors such as disease etiology, cell type, deliv-
ery route, cell retention/engraftment, activation of resident cells,
or functional integration. In order to optimize cell therapies, we
need to improve our understanding of how these factors interact.Cell Stem Cell 14, April 3, 2014 ª2014 Elsevier Inc. 431
Figure 1. Cell Labeling Strategies and Detectors for Stem Cell Imaging
For direct labeling (in green), cells are incubated with imaging probes that enter the cell via transporter uptake (i.e., 18F-FDG, 18F-FESP, and 18F-FHBG),
endocytosis (i.e., SPIONs, QDs, AuNPs and microbubbles), or passive diffusion (i.e., 111In-ox). In reporter gene imaging (in blue), cells are transfected or
transduced with the reporter gene construct. Transcription of the reporter gene under the control of a promoter followed by translation of its mRNA leads to
accumulation of different reporter proteins such as receptors (i.e., D2R), enzymes/proteins (HSVtk, FLuc, RLuc, GFP, and RFP), and transporter proteins (NIS).
Introduction of a reporter gene probe (i.e., 18F-FESP, D-luciferin, coelenterazine) results in signal generation. Labeled cells are detected by imaging systems such
as PET, MRI, CT, ultrasound, FLI, BLI, and SPECT. Abbreviations: 18F-FDG, 18F-Fluorodeoxyglucose; 18F-FESP, 3-(20-[18F]-fluoroethyl)-spiperone; 18F-FHBG,
9-(4-18Ffluoro-3-[hydroxymethyl]butyl) guanine; Glc, glucose; GLUT1, glucose transport type 1; Pyr, pyruvate; TCA, Tricarboxylic acid cycle; TA, transfection
agents; SPIONs, superparamagnetic iron oxide nanoparticles; QDs, quantum dots; AuNPs, gold nanoparticles; 111In-ox, indium oxine; Asp, aspartic acid; Ser,
serine; NIS, sodium iodide symporter; I, iodine; 99 mTcO4
, technetium pertechnetate; D2R, dopamine 2 receptor; HSV-ttk, herpes simplex virus truncated
thymidine kinase; FLuc, firefly luciferase; RLuc, renilla luciferase; GFP, green fluorescent protein; RFP, red fluorescent protein; PET, positron emission to-
mography; MRI, magnetic resonance imaging; CT, computed tomography; FLI, fluorescence imaging; BLI, bioluminescence imaging; SPECT, single-photon
emission computed tomography.
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trials Table 2 has helped answer some of these important ques-
tions, with further discoveries to come. Stem cell imaging
studies, for example, have identified the following barriers,
among others, to clinical translation in either adult or pluripotent
stem cells: (1) limited cell engraftment, survival, and proliferation;432 Cell Stem Cell 14, April 3, 2014 ª2014 Elsevier Inc.(2) poor cell differentiation and maturation; (3) immunogenicity
with allogeneic transplantation; and (4) potential tumorigenicity
with pluripotent stem cell derivatives (Figure 2).
Limited Cell Engraftment, Survival, and Proliferation
To achieve their maximum clinical benefit, stem cells and their
derivatives must engraft, survive, and integrate into the target
Table 1. Comparison of Imaging Techniques for Cell Therapies
Imaging Modality Spatial Resolution
Acquisition
Time
Detection
Limit: Cells Labeling Strategy Advantages Disadvantages
Bioluminescence
imaging (BLI)
(preclinical only)
5–20 mm depending
on depth of signal
seconds 103 reporter gene cheap, simple,
high throughput
small animals only, low
resolution, only 2D
images
Fluorescence
tomography (FMT)
(preclinical only)
2–3 mm seconds to
minutes
106 reporter gene,
fluorescent dye
cheap, simple low resolution, cells
need to be close to
surface
Ultrasound (US)
(preclinical and clinical)
150 mm; –2 mm
depending on depth
seconds to
minutes
not well
characterized
reporter gene,
antibody with
microbubble
cheap, relatively
simple
limited 3D capabilities,
low signal to noise ratio
Single-photon emission
computed tomography
(SPECT) (preclinical
and clinical)
1–2 mm; 8–12 mm minutes 105 reporter gene,
incubation with
radiotracer
3D imaging anatomic reference
required, radioactive
tracer required
Positron emission
tomography (PET)
(preclinical and clinical)
1 mm; 4–6 mm seconds to
minutes
104 reporter gene,
incubation with
radiotracer
3D imaging, high
sensitivity
anatomic reference
required, radioactive
tracer required
Magnetic resonance
tomography (MRI)
(preclinical and clinical)
25–500 mm;
0.5–5 mm
minutes to
hours
104 internalization or
surface labeling
with nanoparticles
or specific ions
3D imaging, good
soft tissue contrast,
no radiation, high
resolution
very expensive,
complicated
Computed tomography
(CT) (preclinical and
clinical)
<50 mm; <1 mm seconds to
minutes
not well
characterized
internalization or
surface labeling
with nanoparticles
3D imaging,
relatively cheap,
high resolution
uses ionizing radiation
Fields in italics indicate parameters specific to clinical systems if they are different from preclinical systems.
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delivered will have a substantial impact on retention, survival,
and function of these cells, determining the optimal site and
timing of delivery is critical. For example, delivering stem-cell-
derived cardiomyocytes into the normal myocardium next to
infarcted tissue might improve their survival, but if these cells
are expected to replace dead cardiomyocytes, they will have
to migrate into the infarcted tissue. Given that neither situation
is ideal, achieving high engraftment and survival rates after trans-
plantation continues to be challenging.
A key factor in determining initial engraftment and retention is
the mode of cell delivery. In animal studies of cardiovascular
disease usingmolecular imaging (Huang et al., 2010; Kraitchman
et al., 2005; Templin et al., 2012), less than 5% of transplanted
stem cells and their derivatives engrafted when delivered
intravenously, regardless of cell type (i.e., mesenchymal stem
cells [MSCs], induced pluripotent-stem-derived cardiomyo-
cytes [iPSC-CMs], embryonic-stem-cell-derived endothelial
cells [ESC-ECs]) and the number of cells implanted. In a direct
head-to-head study comparing cell delivery methods, myocar-
dial retention was highest when peripheral blood mononuclear
cells (PBMNCs) were injected intramyocardially compared to in-
tracoronary or intravenous delivery (11% ± 3% versus 2.6% ±
0.1% versus 3.2% ± 1%) (Hou et al., 2005). Regardless of the
delivery route, however, the majority of stem cells and their de-
rivatives (i.e., MSCs and ESC-ECs) were found in the pulmonary
vasculature, spleen, liver, and microvasculature (Gyo¨ngyo¨si
et al., 2010; Huang et al., 2010; Toma et al., 2009), but not
near the area of injury. Because cell size may potentially con-
tribute to significant egress to extracardiac tissues, deliveringcells as part of a tissue scaffold or graft may improve myocardial
retention (Kraehenbuehl et al., 2011; Seif-Naraghi et al., 2013),
but this has not yet been tested in cell imaging studies.
Some cells, however, do home to areas of injured myocar-
dium, as shown in preclinical cell tracking studies using BLI
and SPECT discussed below. Sheikh et al. demonstrated greater
homing of bone marrow mononuclear cells (BMMNCs) express-
ing firefly luciferase (FLuc) in murine hearts with ischemia/
reperfusion within 1 week of delivery compared to sham hearts
(Sheikh et al., 2007). Their findings were confirmed by histology
and real-time PCR (for the male SryY gene from donor cells).
Similarly, Kraitchman et al. showed a diffuse uptake of indium
oxine (111In-oxine) radiolabelled MSCs at 4 to 7 days posttrans-
plantation in infarcted canine hearts (Kraitchman et al., 2005). In
a murine model of hindlimb ischemia, Huang et al. also showed
that ESC-ECs injected into the femoral vein initially lodged in the
pulmonary circulation but eventually homed in on the ischemic
limb (Huang et al., 2010).
More promising results have been found in models of neuro-
vascular disease. In a study directly comparing intra-arterial
versus intravenous injection of neural stem cells (NSCs) using
BLI in a murine model of hypoxia, Pendharker et al. found that
61% of NSCs were retained in the brain immediately after
intra-arterial injection, which declined only slightly to 55% by
7 days (Pendharkar et al., 2010). The BLI signal in the brain
was 12 times higher after intra-arterial injection compared to
intravenous injection, where the predominant signal was in the
torso. Similar to findings from models of myocardial infarction
as discussed previously, homing to the area of injury has
been noted in models of cerebral injury. Using BLI and MRI,Cell Stem Cell 14, April 3, 2014 ª2014 Elsevier Inc. 433
Table 2. Selected Clinical Studies for Human Cell Transplantation
First Author/Year
Number of
Patients Disease
Number of
Cells/Type
Delivery
Method
Imaging
Modality Labeling Technique
Cell Retention/
Survival (%) Study Observations
Studies based on
nuclear medicine
techniques (SPECT,
PET, GC)
Hofmann et al.
(2005)
9 STEMI 2 to 4.5 3
109 BMC
ICA ICV+ICA PET 18F-FDG BMC or
18F-FDG CD34+
fraction of BMC
2 (ICA, 1.5 hr);
3.8 (ICV+ICA,
1.5 hr); 25 (ICA,
CD34+, 1.5 hr)
homing only to perfused area of
delivery artery, no retention after
ICV, higher retention for CD34+
cells
Karpov et al. (2005) 44 transmural MI 9 3 107
BMMNC
ICA SPECT 99 mTc-HMPAO 6.8 (2.5 hr);
3.2 (24 hr)
no differences in cardiac function
between control and treatment
groups
Kang et al. (2006) 20 STEMI PBMNC ICA ICV PET 18F-FDG 1.5 (ICA, 2 hr);
0 (ICV, 2 hr)
cell retention in old and new
infarcts were not different
Correa et al. (2007) 1 ischemic stroke 3 3 107
BMMNC
OTW LCMA SPECT 99 mTc-HMPAO n/a substantial amount of delivered
cells in brain
Scha¨chinger et al.
(2008)
19 acute-chronic MI 1.5 3 107
PBMNC
OTW ICA GC 111In-oxine 6.9 (1 hr);
2 (3–4 days)
reduced retention in chronic
compared to acute MI
Silva et al. (2009) 30 STEMI 1 3 108
BMMNC
OTW: ICA
or ICV
SPECT 99 mTc-HMPAO 10.3 (ICA, 24 hr);
3.1 (ICV, 24 hr)
six-month LVEF improvement is
correlated with cell retention and
higher in ICA group
Barbosa da
Fonseca et al.
(2010)
6 ischemic stroke 1 to 5 3 108
BMMNC
MCA SPECT
WB GC
99 mTc 1.7 (2 hr) uptake primarily in the hemisphere
with the stroke lesion
Barbosa da
Fonseca et al.
(2011)
6 chagasic cardio-
myopathy
1 to 10 3 108
BMMNC
ICA SPECT
WB GC
99 mTc 5.4 (1 hr);
4.3 (3 hr);
2.3 (24 hr)
homing not correlated with number
of cells administered; poor uptake
in areas with perfusion deficit
Vrtovec et al. (2013) 40 DCM 1 3 108 CD34+
from PBMNC
ICA, IM GC 99 mTc-HMPAO 4.4 (IC, 18 hr);
19.2 (IM, 18 hr)
six-month LVEF improvement is
correlated with cell retention and
higher in IM group
Studies based on
magnetic resonance
imaging (MRI)
Zhu et al. (2006) 2 brain trauma NPC stereo-tactical
injection
3T MRI SPIO n/a migration of cells from injection
site to border of lesion, signal
persistent for 7 weeks
Callera and de
Melo (2007)
16 spinal cord injury 0.7 3 106
CD34+ from
PBMNC
lumbar
puncture
1T MRI antibody: SPIO n/a cell migration 35 days after
injection, cells were not detected
in 50% of patients
STEMI, ST elevation myocardial infarction; BMC, bone marrow cells; ICA, intracoronary artery infusion; ICV, intracoronary vein infusion; IM, intramyocardial delivery; PET, positron emission tomog-
raphy; 18F-FDG, 18F-Fluorodeoxyglucose; MI, myocardial infarction; BMMNC, bone marrow mononuclear cells; SPECT, single-photon emission computed tomography; 99 mTc-HMPAO, 99 mTc-
hexamethylpropyleneamine oxime; PBMNC, peripheral blood mononuclear cells; OTW, over the wire balloon infusion; LCMA, left cerebral middle artery; GC, gamma scintillation camera; LVEF,
left ventricular ejection fraction; MCA, middle cerebral artery; WB GC, whole body gamma scintillation camera; DCM, dilated cardiomyopathy; SPIO, superparamagnetic iron oxide nanoparticle;
NPC, neuronal progenitor cells.
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Figure 2. Barriers to Clinical Translation
A variety of stem cell types (e.g., adult somatic cells, induced pluripotent stem cells, and embryonic stem cells) are available for transplantation, each with their
advantages and disadvantages. Adult somatic stem cells aremost commonly transplanted directly into the recipient, whereas embryonic and induced pluripotent
stem cells undergo in vitro differentiation prior to transplantation. Regardless of the stem cell type, their successful application in regenerative therapy faces
similar clinical hurdles, including (1) limited engraftment, survival, and proliferation; (2) poor differentiation, maturation, and integration; (3) immunogenicity with
allogeneic transplantation; and (4) potential tumorigenicity with pluripotent stem cell derivatives. Cell imaging plays a pivotal role in overcoming these hurdles and
will help guide the translation of this promising therapy.
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Reviewinvestigators have tracked ESCs labeled with superparamag-
netic iron oxide nanoparticles (SPIONs) and neuroprogenitor
cells transfected with FLuc as they move from their injection
site in the contralateral hemisphere, across the corpus callosum,
and to the injured hemisphere (Hoehn et al., 2002; Kim et al.,
2004). Importantly, cells injected into sham mice did not show
any evidence of migration.
Reminiscent of results from preclinical studies discussed pre-
viously, cell-tracking studies in humans demonstrate low cell
retention rates, regardless of delivery method. SPECT and PET
are by far the most frequently applied techniques in clinical
biodistribution studies. The majority of studies have been per-
formed in patients for the treatment ofmyocardial infarction (Hof-
mann et al., 2005; Kang et al., 2006; Karpov et al., 2005). In one of
the initial cell tracking studies, Karpov et al. reported that only
6.8% of autologous BMMNCs labeled with 18F-Fluorodeoxyglu-
cose (18F-FDG) were retained in the heart 2.5 hr after intracoro-nary cell infusion (Karpov et al., 2005). Hofmann et al. found
higher retention rates with intracoronary delivery (2%) compared
to coronary vein delivery (undetectable) 1.5 hr after infusion of
BMMNCs (Hofmann et al., 2005). Interestingly, the subset of
CD34+ bone marrow cells had a significantly higher retention
rate of almost 25%. A modest improvement in retention was
also achieved by inflating a balloon to temporarily stop blood
flow. Using this modified technique, retention of BMMNCs
24 hr after intracoronary artery or coronary vein delivery
increased slightly to 10.3% and 3.1%, respectively (Silva et al.,
2009). A more recent study demonstrated that intramyocardial
injection of CD34+ cells labeled with 99 mTc-hexamethylpropy-
lene amine oxime (99 mTc-HMPAO) could significantly improve
cell retention to 19% at 18 hr after cell delivery (Vrtovec et al.,
2013). Unfortunately, the short half-life of radioactive tracers
used in the aforementioned studies (i.e., 1.83 hr for 18F-FDG
and 6 hr for 99 mTc-HMPAO) did not allow a longer duration ofCell Stem Cell 14, April 3, 2014 ª2014 Elsevier Inc. 435
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Reviewtracking. Using radioactive 111In-oxine, which has a longer half-
life of 2.8 days, Scha¨chinger et al. found that the number of re-
tained cells dropped from 6.9% at 1 hr to 2% after 3–4 days
(Scha¨chinger et al., 2008).
In addition to initial cell engraftment, cell survival may be
necessary to achieve maximal therapeutic benefit. Unfortu-
nately, cell tracking studies using BLI in small animal models of
myocardial infarction have demonstrated poor survival after
transplantation ofMSCs (van der Bogt et al., 2008), skeletal myo-
blasts (van der Bogt et al., 2008), BMMNCs (van der Bogt et al.,
2008), adipose stromal cells (van der Bogt et al., 2008), cardiac
resident stem cells (Li et al., 2009), ESC-ECs (Li et al., 2007,
2008), and ESC-CMs (Cao et al., 2008). Similarly, in a large ani-
mal model of myocardial infarction, Gyo¨ngyo¨si et al. failed to
detect the presence of porcine MSCs transfected with a PET re-
porter gene at 7 days after allotransplantation (Gyo¨ngyo¨si et al.,
2008). Likewise, in murine models of myocardial infarction using
BLI, the majority of MSCs (Hoffmann et al., 2010), ESC-ECs
(Huang et al., 2010), and iPSC-ECs died shortly after transplan-
tation (Rufaihah et al., 2011).
Interestingly, better long-term survival has been achieved in
small animal models of brain injury using human NSCs (Guzman
et al., 2007), human-ESC-derived NSCs (Daadi et al., 2009), and
bone-marrow-derived MSCs (Sykova and Jendelova, 2007). In
an MRI tracking study, Guzman et al. showed in a rat model of
distal middle cerebral artery occlusion that an average of
51.3% (range: 38.9%–74.6%) of human NSCs survived at
5 weeks after stereotactic injection, which was verified by histo-
logical staining for the human-specific marker SC121 (Guzman
et al., 2007). However, survival may be overestimated because
of the engulfment of dead cells containing SPIONs by macro-
phages, leading to false-positive signal generation (Li et al.,
2008; Terrovitis et al., 2008). To address this question, Daadi
et al. labeled human NSCs with both SPIONs and the FLuc re-
porter gene and demonstrated stable SPIO and BLI signal up
to 2 months posttransplantation (Daadi et al., 2009). Importantly,
the in vitro cell dose-BLI relationship was maintained in vivo and
correlated well with the SPIO dose relationship, suggesting that
MRI of SPIONs might be a suitable method for cell tracking in
stroke models. Taken together, these findings suggest that the
environmental milieu of the central nervous system (CNS) may
be less hostile to stem cell engraftment and survival than the
cardiovascular system.
Not only does the host environment change depending on the
target organ, but it may also vary based on the time after injury.
Shortly aftermyocardial infarction, for example, the host environ-
ment may be hostile to cell viability because of the presence of
inflammatory cells that are recruited to repair the injuredmyocar-
dium. As scar tissue forms in the myocardium, the injured area
may be devoid of vasculature, which may also impair cell sur-
vival. Interestingly, a preliminary study by Swijnenburg et al.
showed that timing of delivery actually has little impact on the
overall survival of BMMNCs and subsequent change in LVEF in
both acute (<2 hr) and subacute (7 days) models of myocardial
infarction (Swijnenburg et al., 2010). Additional imaging studies
are needed to determine whether delivery of cells at later
times (e.g., 2–4 weeks after myocardial infarction when the in-
flammatory response has subsided) may indeed improve cell
engraftment.436 Cell Stem Cell 14, April 3, 2014 ª2014 Elsevier Inc.Interestingly, timing of delivery has also been shown to affect
cell differentiation in stroke models. Rosenblum et al. used the
reporter genes FLuc and green fluorescent protein (GFP) to
assess in vivo survival and ex vivo phenotypic differentiation,
respectively, after intra-arterial delivery of NSCs. Improved sur-
vival was noted 3 days after transplantation when levels of
vascular adhesion molecules that promote cell homing were
highest (Rosenblum et al., 2012). Moreover, early transplantation
(i.e., 6 and 24 hr) led to greater differentiation into astrocytes
rather than neurons, which were more predominant with later
(7 and 14 days) transplantation times. Transplantation at
3 days postinjury resulted in a more even distribution of astro-
cytes and immature neurons.
Long-term cell tracking in humans presents a greater chal-
lenge. Radioactive tracers with short half-lives that are more
commonly used in clinical stem cell imaging studies are not suit-
able to assess cell migration due to a short tracking period and
limited resolution. The persistence of SPIONs in labeled cells
together with the high resolution and superior soft tissue contrast
makes long-term clinical cell tracking with MRI feasible. De Vries
et al. showed that SPIO-labeled dendritic cells injected into
lymph nodes could be readily detected, in addition to theirmigra-
tion to draining lymph nodes 2 days after injection (de Vries et al.,
2005). By colabeling these cells with 111In-oxine for visualization
by SPECT, the investigators also demonstrated that high spatial
resolution for MRI is critical for confirmation of transplantation
success. Because of its lower spatial resolution, SPECT did
not accurately locate the lymph nodes in three patients, resulting
in injection of dendritic cells into the surrounding fat. Moreover,
SPECT provided limited visualization of migration to several
draining lymph nodes, which were resolved by MRI. In a second
study, Callera et al. used SPIO-labeled CD34+ cells injected into
the spines of patients with spinal cord injury to assess the cells’
migratory capacity (Callera and de Melo, 2007). MRI at 20 and
35 days after cell delivery was able to detect injected cells and
showed their migration toward the side of injury. MRI-based
detection of cell migration has also been performed for NSCs in-
jected into patients with brain trauma and has yielded evidence
for the presence of NSCs for up to 3 weeks after cell injection
(Zhu et al., 2006). These and other examples demonstrate the
feasibility of using MRI for cell tracking (see Table 2).
The advantages of MRI are high resolution, good contrast, and
label persistence. However, it is difficult to estimate bio-
distribution, initial cell retention, or cell numbers with MRI. In
addition, the persistence of SPIONs can also be a disadvantage
because resident macrophages can take up the particles after
delivered cells have died, leading to false-positive signals for
cell retention or survival (Li et al., 2008; Terrovitis et al., 2008).
These potential confounding factors need to be considered
when interpreting cell migration of magnetically labeled cells
with MRI, particularly for long-term cell tracking. Interestingly,
the ability of macrophages to take up free SPIONs can be
used to label them in the human body and track their migration
to sites of inflammation (Yilmaz et al., 2013). Combining radioac-
tive labeling or reporter gene imaging with MRI tracking might be
the best solution if initial cell retention and spatial localization
have to be determined.
Although reporter gene imaging has become very widespread
in preclinical studies as discussed previously, only one study has
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in humans (Yaghoubi et al., 2009). Viability of genetically modi-
fied T cells expressing herpes simplex virus type 1 thymidine ki-
nase (HSV1-tk) could be assessed a few days after cell delivery.
This approach could track transplanted cells in the human body
as long as they remain alive and would also be suitable to assess
proliferative capacity of transplanted cells. Reporter gene imag-
ing, however, requires genetic modification of transplanted cells,
which increases the regulatory complexity for their approval
and poses additional risks for mutagenesis. Furthermore, the
repeated use of radioactive tracers would expose the patient
to higher radiation doses. Nevertheless, the potential value of
the information that could be gained and improved methods
for genetic transformation may justify the use of this technique
in the future.
Whether cellular proliferation after implantation can compen-
sate for low levels of retention and survival remains unclear.
Signal increase is frequently inferred as proliferation and often
occurs early after transplantation of adult progenitor or differen-
tiated cells prior to signal decline as cells die. Progressive signal
increase has been reported after transplantation of undifferenti-
ated ESCs and iPSCs (Cao et al., 2007b, 2009; Gutierrez-Aranda
et al., 2010; Lee et al., 2009) in animal models of myocardial
infarction, corresponding to the development of a teratoma.
Overreliance on this measure, however, may lead to the under-
estimation of true proliferation rates because replacement of
dying cells is not accounted for. Direct imaging of cell prolifera-
tion requires the utilization of radiotracers involved in the thy-
midine salvage pathway of DNA synthesis (e.g., thymidine
analogs), because thymidine contains the only pyridine or purine
base that is unique to DNA. Direct imaging of in vivo stem cell
proliferation has not yet been performed in animals or humans,
but it has been reported in studies tracking tumor progression
(Bading and Shields, 2008).
Poor Differentiation, Maturation, and Integration
It is hoped that once cells are delivered and engraftment takes
place, they will differentiate, mature, and integrate into the target
organ, resulting in tissue regeneration. However, in vivo differen-
tiation of ESCs and iPSCs is hampered by the difficulty of direct-
ing differentiation toward the target cell type because the host
tissue milieu may lack the complex array of signaling sequences
required for directed differentiation and maturation (Cao et al.,
2008), leading to the development of teratomas (Cao et al.,
2007b, 2009; Gutierrez-Aranda et al., 2010; Lee et al., 2009).
Due to the challenges of in vivo differentiation and the relative
ease of in vitro differentiation where reagents can be added un-
der controlled conditions, numerous protocols have emerged for
in vitro cardiac differentiation (Burridge et al., 2012) and neural
differentiation (Kim et al., 2009). Although robust differentiation
to cardiac and neural cells is now feasible, generating specific
cell subtypes can be more difficult (e.g., atrial versus nodal
versus ventricular), highlighting the need for better understand-
ing of the signaling pathways associated with cellular differenti-
ation.
Most differentiated stem cell populations exhibit immature
features, which may hamper their ability to treat disease. ESC-
CMs and iPSC-CMs, for example, exhibit a neonatal form of
gap junction distributions, which have slower conduction veloc-
ities (Chen et al., 2009). These gap junction connections arerandomly distributed at the contact interfaces and do not align
properly, making the action potentials across these interfaces
less predictable and less homogeneous, which may lead to the
development of arrhythmias after cell transplantation.
Because of the slow maturation of certain neuronal subtypes,
generatingmature functional neurons has also been challenging.
Most interneuron precursors derived from human ESCs retain
undifferentiated features and even those in a more differentiated
state still express neural precursor markers within 1 to 2 months
after transplantation (Maroof et al., 2013). Development into
functional GABAergic interneurons can take up to 7 months
in vitro and after transplantation (Nicholas et al., 2013).
In addition to maturation, structural and functional (i.e., electri-
cal andmechanical) integration within the target organ is needed
for effective tissue regeneration. Preliminary studies based on
ex vivo histopathological data indicate that transplanted stem
cells do, at least partially, integrate into the heart and brain (Ke-
hat et al., 2004; Shiba et al., 2012; Wernig et al., 2004). Kehat
et al. demonstrated that transplanted human ESC-CMs suc-
cessfully paced the hearts of swine with complete heart block
(Kehat et al., 2004). Although electroanatomical mapping and
subsequent histopathological analysis demonstrated that the
focus of ventricular activation was the site of cell transplantation,
it is possible that pacing resulted from the effects of the ESC-
CMs on the host myocardium rather than the cells themselves.
Further support for electrical-mechanical coupling was provided
by Shiba et al., who showed that guinea pigs grafted with human
ESC-CMs had improved mechanical function and lower inci-
dence of arrhythmias (Shiba et al., 2012). By creating human
ESC-CMs grafts that stably transfected a fluorescent calcium
sensor, the authors showed that calcium fluorescent signal re-
corded in transplanted grafts synchronized 1:1 with systole
(i.e., the phase of left ventricular contraction) on the electrocar-
diogram (Shiba et al., 2012).
Likewise, Wernig et al. showed that synapses form between
the embryonic rat host and donor ESC-derived neuroprecursors
in the brain, as supported by the expression of postsynaptic
density 95 (PSD-95) of donor cell dendrites on ex vivo histopath-
ological analysis and confirmed by ultrastructural and electro-
physiological data (Wernig et al., 2004). However, not all of the
transplanted neuronal cells expressed regionally appropriate
transcription factors, which are important regulators of the
brain’s regional-specific activity.
Currently, evaluation of stem cell differentiation, maturation,
and integration relies primarily on ex vivo histological examina-
tion and, thus, has been limited to animal studies as discussed
previously. In vivo monitoring will enable investigators to poten-
tially direct these processes to improve efficacy. Investigators
reported an approach to image differentiation using a promoter
of a differentiation-specific gene to drive the expression of an
established reporter gene, the sodium/iodide symporter (NIS).
Kang et al. created a transgenic mouse carrying a reporter
gene construct driven by an alpha myosin heavy chain (MHC)
promoter in transgenic mice. When exposed to radioactive
iodine, the myocardium of transgenic mice showed rapid,
increased uptake that was abolished by oral administration of
potassium perchlorate, an NIS inhibitor (Kang et al., 2005). Using
an alternative strategy, Xie et al. monitored changes in the
expression of signal transducers and activators of transcriptionCell Stem Cell 14, April 3, 2014 ª2014 Elsevier Inc. 437
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renilla luciferase (RLuc) during the in vitro differentiation of
mouse ESCs (Xie et al., 2009).
Immunogenicity Associated with Allogeneic
Transplantation
As in solid organ transplantations, the immune system remains a
formidable barrier to the clinical implementation of stem cell ther-
apy. Poor cell survival after stem cell implantation is partly due to
cellular rejection by the immune system (de Almeida et al., 2013;
Pearl et al., 2012). Even pluripotent stem cells, which were once
considered potentially immunoprivileged due to their lack of
major histocompatibility complex (MHC) class I, MHC class II,
and costimulatory molecules, as well as their expression of
immune-modulating molecules (Abdullah et al., 2007; Koch
et al., 2008; Magliocca et al., 2006), have been found to elicit a
donor-specific immune response when transplanted into im-
mune competent mice (Drukker et al., 2006; Swijnenburg et al.,
2008a). Although the discovery of iPSCs offered a potential solu-
tion to immune rejection (Takahashi et al., 2007; Yu et al., 2007),
Zhao et al. reported that murine iPSCs were also rejected after
transplantation into syngeneic recipients (Zhao et al., 2011).
However, two recent studies by Araki et al. and Guha et al.
have disputed that claim; the authors showed that transplanta-
tion of tissue grafts derived from iPSC-derived mice (e.g., skin
and bone marrow) and terminally differentiated iPSC derivatives
(e.g., endothelial cells, hepatocytes, and neuronal cells), respec-
tively, may be less immunogenic, reigniting hope that iPSCs can
still be used to circumvent the immune system (Araki et al., 2013;
Guha et al., 2013). Both of the aforementioned studies relied on
ex vivo histopathological analysis.
Improvement in survival can be achieved by transplantation
into a more immune-tolerant tissue environment. Because the
blood-brain barrier separates the CNS from the systemic
immune system, the brain is considered more immunoprivileged
than other sites of the body, enabling the long-term survival of
stem cells as discussed previously (Daadi et al., 2009; Guzman
et al., 2007). An alternative strategy is to transplant cells into a
more immune tolerant recipient host, which has been shown to
be successful in the following small animal cell tracking studies.
Using BLI, Swijnenburg et al. found poor survival of cells trans-
planted into immunocompetent mice compared to immuodefi-
cient mice, with marginal improvement in survival achieved by
administration of traditional immunosuppressive regimens (i.e.,
tacrolimus, sirolimus, and myocophenolate mofetil) (Swijnen-
burg et al., 2008b). In a follow-up study using BLI, improved
engraftment and survival of ESCs, iPSCs, and their differentiated
derivatives was achieved by the administration of costimulatory
receptor blocking agents such as cytotoxic T-lymphocyte-asso-
ciated antigen 4 (CTLA4)-Ig, anti-CD40 ligand (anti-CD40L),
and anti-lymphocyte function-associated antigen 1 (anti-LFA-1)
(Huber et al., 2013; Pearl et al., 2011). More recently, a study
by Rong et al. based on ex vivo histopathological data found
that constitutive expression of CTL4-Ig and programmed death
ligand-1 (PD-L1) in human ESCs were not rejected in humanized
mice, which showed reduced infiltration of human T cells (Rong
et al., 2014). Furthermore, infiltrating T cells expressed high
levels of immunosuppressive cytokines.
To avoid the potential side effects of immunosuppressants
that can increase morbidity and mortality, studies using ex vivo438 Cell Stem Cell 14, April 3, 2014 ª2014 Elsevier Inc.histopathological analysis are currently evaluating encapsulation
of MSCs into an artificial semipermeable membrane as a
means for evading the immune system for applications that
do not require direct interaction of transplanted cells with the
host tissue (Levit et al., 2013). In animal models of myocardial
infarction, transplantation of encapsulated human MSCs has
been shown to improve cell survival and efficacy, compared to
implantation of nonencapsulated counterparts (Levit et al.,
2013).
Direct monitoring of transplant cell rejection has not been eval-
uated and is currently inferred indirectly by the progressive
decline of labeled cells posttransplantation. Christen et al. pro-
posed a promising technique to directly image immune cells
involved in transplant rejection, namely, macrophages, which
release proteases and phagocytose dead or dying cells (Christen
et al., 2009). Using a fluorescent protease sensor and a magne-
tofluorescent phagocytosis marker, the investigators created a
3D functional map showing higher phagocytosis activity on
MRI during rejection and higher protease activity on tomo-
graphic FLI in mice receiving cardiac allografts than in those
receiving isografts. Strategies such as this will enhance the dis-
covery of novel tolerance-inducing agents to improve survival of
transplanted cells.
Potential Tumorigenicity Associated with Pluripotent
Stem Cell Transplantation
The risk for tumor formation is low for adult somatic stem cells
and progenitors, whose differentiation is largely limited to the
different cell types of their tissue of origin. Given their better
safety profile, somatic cells as well as progenitor cells are
currently being evaluated in clinical trials. Nevertheless, in vivo
cell tracking is still needed to monitor long-term safety after de-
livery of these cells, as demonstrated by a recent case report of a
boy with ataxia telangiectasia who developed a glioneuronal
brain tumor 4 years after intracerebellar and intrathecal injection
of fetal neural stem cells (Amariglio et al., 2009).
Because they arise from pluripotent stem cells, ESC and iPSC
derivatives may pose a greater risk for tumor development.
These cells can malignantly transform, resulting in the formation
of a teratoma, a tumor consisting of cells from all three germ
layers. Alternatively, it is possible that a preparation of ESC or
iPSC derivatives could be contaminated with undifferentiated
or incompletely differentiated cells that can proliferate and
form a teratoma (Cao et al., 2007b; Gutierrez-Aranda et al.,
2010; Lee et al., 2009).
In order to prevent tumor development, a pure cell product
must be obtained prior to transplantation. Product purity can
be achieved by depletion of undifferentiated cells (Ben-David
et al., 2013a, 2013b; Tang et al., 2011) or enrichment of differen-
tiated cells based on their expression of specific surfacemarkers
(Dubois et al., 2011), which is ascertained using either fluores-
cent activated cell sorting (FACS) or magnetic activated cell sort-
ing (MACS), the latter being more amenable for high-throughput
processing. Because 100% purity may be difficult to attain, it will
be important to define a minimum threshold of undifferentiated
cells that can be tolerated. Based on a previous study using
BLI in immunodeficient mice to track the growth of teratomas
originating from ESCs transduced with a construct expressing
FLuc and GFP, it appears that a ‘‘pure’’ cell product cannot
contain more than 104 undifferentiated cells, the threshold
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2009). Even lower thresholds may be required based on other
cell tracking reports (Cao et al., 2007b).
The removal of potential tumorigenic cells, however, will not
preclude the need for tumor surveillance by more traditional
imaging techniques (e.g., ultrasound, computed tomography,
or MRI) to identify abnormal growths or cellular activity (e.g.,
PET). Earlier detection may require the use of molecular imaging
probes, such as the PET reporter probe 64Cu-radiolabeled cyclic
Arg-Gly-ASP (RGD) peptides, to image expression of aVb3 integ-
rins, which play an important role in angiogenesis and metas-
tasis. Cao et al. demonstrated the superiority of this technique
compared to more standard 18F-FDG and 18F-Fluorothymidine
(18F-FLT) PET imaging for detecting teratoma formation fol-
lowing subcutaneous injection in mice (Cao et al., 2009). Alterna-
tively, the PET reporter gene herpes simplex virus truncated
thymidine kinase (HSV-ttk) can serve as both a monitor for tumor
development and a suicide gene for ablative therapy (Cao et al.,
2007a). Specifically, Cao et al. transplanted mice with ESCs
labeled with either a double-fusion (GFP and FLuc) or a triple-
fusion (GFP, RLuc, and HSV-ttk) construct. BLI detected tera-
toma formation in both groups after 5 weeks, but only those
teratomas expressing HSV-ttk were ablated by the administra-
tion of gancyclovir, which competitively inhibits the incorporation
of deoxyguanosine triphosphate into DNA and the function of
viral DNA polymerase.
The Future of Stem Cell Imaging
Although significant insight has been gained from incorporating
in vivo imaging in preclinical studies, its application in clinical
trials remains underutilized and perhaps undervalued. Molecular
imaging provides much needed ‘‘pharmacokinetic’’ information
for the safe and effective administration of cellular therapies.
For example, when examining a patient’s response to stem cell
therapies in clinical trials, individual variation is significant (Alper,
2009; Bang et al., 2005; Bolli et al., 2011; Hare et al., 2012; Held-
man et al., 2014; Kondziolka et al., 2005; Perin et al., 2012), with
some patients in the therapy group achieving little or no improve-
ment while some have significant functional recovery. Unfortu-
nately, these pivotal trials did not incorporate cell tracking,
leaving us with many unanswered questions. It is possible if
not likely that individual patients might have different reactions
to the therapy administered, and the transplanted cells did not
engraft or survive in those that did not respond to therapy. As
ESC and iPSC derivatives enter clinical trials (Garber, 2013), it
will also be important to determine whether inadequate differen-
tiation, maturation, and integration could also lead to poor
functional outcome. Although strategies to monitor the latter
processes are still in their infant stages andwill need to be further
explored in animal models, short-term tracking of engraftment
and survival of cells directly labeled with imaging probes is
currently feasible in humans and could be utilized in future
stem cell trials (see Table 2).
At a minimum, molecular imaging should be incorporated into
clinical phase II trials to generate a dose response curve to iden-
tify the optimal dose and dosing frequency. Depending on the
efficacy readout, estimating dose response could be performed
purely on the number of cells engrafted. In line with that, both
preclinical and clinical studies using molecular imaging havefound a considerable variability in the degree of cell retention,
which was not correlated with the number of administered cells
(Barbosa da Fonseca et al., 2011; Correa et al., 2007; Dedobbel-
eer et al., 2009; Scha¨chinger et al., 2008). This makes dose
response estimates more difficult because of the need for sub-
stantial group sizes. Despite the small number of patients
enrolled, two recent clinical studies were able to find a positive
correlation between early cell retention by cell imaging and late
improvement in cardiac function 6 months after cell delivery
(Silva et al., 2009; Vrtovec et al., 2013).
Molecular imaging can play a more extensive role by evalu-
ating strategies to improve the viable cell concentration at the
target site. As demonstrated in a growing number of preclinical
studies but only a handful of clinical studies, cell imaging can
help define the optimal cell type, delivery method (Hofmann
et al., 2005; Vrtovec et al., 2013), timing of delivery (Rosenblum
et al., 2012; Swijnenburg et al., 2010), and host microenviron-
ment (Pearl et al., 2011; Swijnenburg et al., 2008b). Large-scale
clinical studies incorporating molecular imaging are needed to
determine which strategies will prove to be the most efficacious.
The other important role that cell imaging provides is to
decrease toxicity to patients. The optimal cell dose must not
only lead to maximal benefit, but also result in minimal risk of
tumor formation, which is likely specific to the cell subtype and
the injection site (Lee et al., 2009), and perhaps even specific
to the patient. Molecular imaging can identify early transforma-
tion of cell grafts into tumors by imaging the proliferation and/
or expression of tumor-specific markers (Cao et al., 2009), which
cannot be detected by traditional imaging techniques.
Further optimization of cellular therapy will require implemen-
tation of reporter gene imaging in humans, which will enable
long-term assessment of survival and proliferation as well as dif-
ferentiation, maturation, and integration. Adequate tumor sur-
veillance will also require long-term imaging. Although the use
of reporter gene imaging for long-term cell tracking in humans
is currently restricted by regulatory hurdles, reservations about
safety may be addressed by the use of human endogenous ver-
sions of reporter genes (e.g., human ferritin reporter for MRI
[Campan et al., 2011] and human mitochondrial thymidine-
kinase-2 for PET [Ponomarev et al., 2007]. To avoid the problem
of insertional mutagenesis, safety can be further enhanced by
applying newer methods for genomic manipulation such as
site-specific integration using phage integrases (Karow et al.,
2011; Lan et al., 2012) and safe harbor mediated integration by
zinc-finger nuclease (ZFN) (Ochiai et al., 2012; Wang et al.,
2012), transcription activator-like effector nuclease (TALEN)
(Sommer et al., 2014), or clustered regularly interspaced short
palindromic repeats (CRISPR) (Yang et al., 2013).
In the future, we predict that molecular imaging will be per-
formed regularly throughout the course of treatment. From the
time of delivery, patients will bemonitored for safety and efficacy
to identify those at risk for tumor formation or those that may
benefit from repeat transplantation, respectively (Figure 3).
PET/MRI will likely emerge as the imaging modality of choice,
given that it provides exquisite functional and anatomical detail
with minimal radiation exposure. Although molecular imaging
in humans is restricted to short-term monitoring of engraftment
and survival, investigators are encouraged to use the tools at
hand to guide the clinical translation of stem cell therapy. WithCell Stem Cell 14, April 3, 2014 ª2014 Elsevier Inc. 439
Figure 3. A Step-by-Step Approach to Successful Routine Application of Stem Cell Regenerative Therapy
Step 1: Stem cell isolation and purification. Stem cells must be initially isolated and purified from a tissue source. Because of poor in vivo differentiation, cells are
often differentiated in vitro prior to implantation. These techniques, however, are imperfect and can result in a mixture of undifferentiated and differentiated cells.
Cell sorting is then required to select for the cell population that can be safely transplanted with maximal therapeutic benefit. Step 2: Cell labeling and trans-
plantation. Prior to transplantation, cells are labeled to enable the tracking of cell fate. Selected cells are labeled in vitro using direct labeling or reporter gene
techniques and are then implanted at the bedside via intravenous delivery or in the operating room/angiography suite, via intralesional or intra-arterial delivery,
respectively. Step 3: Serial imaging for safety and efficacy monitoring. After delivery, labeled cells are tracked using PET/MRI, which provides high sensitivity for
cell detection as well as excellent spatial localization. Cells can be tracked serially to determine whether they engraft, survive, and proliferate in the target organ.
Cells can also bemonitored for any potential unwanted effects including tumor formation andmigration to other sites. In addition, PET/MRI can provide serial data
on the functional and structural recovery of damaged tissues.
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intricate processes as stem cell differentiation and integration
will become feasible, as will longer-term tracking, which will
enable tracking cell fate beyond engraftment and survival.
Finally, it is vital that we conduct more studies to evaluate the
relationship between cell fate and functional improvement to
confirm the efficacy of cell transplantation.
Summary
Although significant progress has been made in the field of
regenerative medicine, stem cell therapies are still in their in-
fancy. Preclinical studies have helped in identifying barriers to440 Cell Stem Cell 14, April 3, 2014 ª2014 Elsevier Inc.clinical translation, but additional studies must be performed to
define strategies to overcome these hurdles. Disappointing re-
sults from clinical trials thus far suggest that we should perhaps
reconsider fundamental strategies while continuing to broaden
the application of stem cell imaging for future clinical trials.
This could be achieved by refining and expanding the available
technologies to enable long-term tracking of cell fate.ACKNOWLEDGMENTS
This work was supported in part by grants from the American Heart Associa-
tion (P.K.N.), Austrian Science Foundation (J.R.), NIH HL093172, NIH
Cell Stem Cell
ReviewEB009689, NIH HL095571, CIRM TR3-05556, and CIRM DR2-05394 (J.C.W.).
Wewould like to give a special thanks to Christina Sicoli Design for creating the
figures. We also thank Blake Wu and Ian Chen for assistance with manuscript
preparation. Due to space limitation, we were unable to include all the impor-
tant relevant papers in stem cell imaging. We apologize to the investigators
who have made significant contributions to this field not discussed in this Re-
view.
REFERENCES
Abdullah, Z., Saric, T., Kashkar, H., Baschuk, N., Yazdanpanah, B., Fleisch-
mann, B.K., Hescheler, J., Kro¨nke, M., and Utermo¨hlen, O. (2007). Serpin-6
expression protects embryonic stem cells from lysis by antigen-specific
CTL. J. Immunol. 178, 3390–3399.
Alper, J. (2009). Geron gets green light for human trial of ES cell-derived prod-
uct. Nat. Biotechnol. 27, 213–214.
Amariglio, N., Hirshberg, A., Scheithauer, B.W., Cohen, Y., Loewenthal, R.,
Trakhtenbrot, L., Paz, N., Koren-Michowitz, M., Waldman, D., Leider-Trejo,
L., et al. (2009). Donor-derived brain tumor following neural stem cell
transplantation in an ataxia telangiectasia patient. PLoS Med. 6,
e1000029.
Antonic, A., Sena, E.S., Lees, J.S., Wills, T.E., Skeers, P., Batchelor, P.E.,
Macleod, M.R., and Howells, D.W. (2013). Stem cell transplantation in trau-
matic spinal cord injury: a systematic review and meta-analysis of animal
studies. PLoS Biol. 11, e1001738.
Araki, R., Uda, M., Hoki, Y., Sunayama, M., Nakamura, M., Ando, S., Sugiura,
M., Ideno, H., Shimada, A., Nifuji, A., and Abe, M. (2013). Negligible immuno-
genicity of terminally differentiated cells derived from induced pluripotent or
embryonic stem cells. Nature 494, 100–104.
Bading, J.R., and Shields, A.F. (2008). Imaging of cell proliferation: status and
prospects. J. Nucl. Med. 49 (Suppl 2 ), 64S–80S.
Bang, O.Y., Lee, J.S., Lee, P.H., and Lee, G. (2005). Autologous mesenchymal
stem cell transplantation in stroke patients. Ann. Neurol. 57, 874–882.
Barbosa da Fonseca, L.M., Xavier, S.S., Rosado de Castro, P.H., Lima, R.S.,
Gutfilen, B., Goldenberg, R.C., Maiolino, A., Chagas, C.L., Pedrosa, R.C.,
and Campos de Carvalho, A.C. (2011). Biodistribution of bone marrow mono-
nuclear cells in chronic chagasic cardiomyopathy after intracoronary injection.
Int. J. Cardiol. 149, 310–314.
Barbosa da Fonseca, L.M., Gutfilen, B., Rosado deCastro, P.H., Battistella, V.,
Goldenberg, R.C., Kasai-Brunswick, T., Chagas, C.L., Wajnberg, E., Maiolino,
A., Salles Xavier, S., et al. (2010). Migration and homing of bone-marrowmono-
nuclear cells in chronic ischemic stroke after intra-arterial injection. Exp Neurol
221, 122–128.
Ben-David, U., Gan, Q.F., Golan-Lev, T., Arora, P., Yanuka, O., Oren, Y.S.,
Leikin-Frenkel, A., Graf, M., Garippa, R., Boehringer, M., et al. (2013a).
Selective elimination of human pluripotent stem cells by an oleate synthesis
inhibitor discovered in a high-throughput screen. Cell Stem Cell 12,
167–179.
Ben-David, U., Nudel, N., and Benvenisty, N. (2013b). Immunologic and chem-
ical targeting of the tight-junction protein Claudin-6 eliminates tumorigenic
human pluripotent stem cells. Nat Commun 4, 1992.
Bolli, R., Chugh, A.R., D’Amario, D., Loughran, J.H., Stoddard, M.F., Ikram, S.,
Beache, G.M., Wagner, S.G., Leri, A., Hosoda, T., et al. (2011). Cardiac stem
cells in patients with ischaemic cardiomyopathy (SCIPIO): initial results of a
randomised phase 1 trial. Lancet 378, 1847–1857.
Burridge, P.W., Keller, G., Gold, J.D., and Wu, J.C. (2012). Production of de
novo cardiomyocytes: human pluripotent stem cell differentiation and direct
reprogramming. Cell Stem Cell 10, 16–28.
Callera, F., and deMelo, C.M. (2007). Magnetic resonance tracking of magnet-
ically labeled autologous bone marrow CD34+ cells transplanted into the spi-
nal cord via lumbar puncture technique in patients with chronic spinal cord
injury: CD34+ cells’ migration into the injured site. Stem Cells Dev. 16,
461–466.
Campan, M., Lionetti, V., Aquaro, G.D., Forini, F., Matteucci, M., Vannucci, L.,
Chiuppesi, F., Di Cristofano, C., Faggioni, M., Maioli, M., et al. (2011). Ferritin
as a reporter gene for in vivo tracking of stem cells by 1.5-T cardiacMRI in a ratmodel of myocardial infarction. Am. J. Physiol. Heart Circ. Physiol. 300,
H2238–H2250.
Cao, F., Drukker, M., Lin, S., Sheikh, A.Y., Xie, X., Li, Z., Connolly, A.J., Weiss-
man, I.L., and Wu, J.C. (2007a). Molecular imaging of embryonic stem cell
misbehavior and suicide gene ablation. Cloning Stem Cells 9, 107–117.
Cao, F., van der Bogt, K.E., Sadrzadeh, A., Xie, X., Sheikh, A.Y., Wang, H.,
Connolly, A.J., Robbins, R.C., and Wu, J.C. (2007b). Spatial and temporal
kinetics of teratoma formation from murine embryonic stem cell transplanta-
tion. Stem Cells Dev. 16, 883–891.
Cao, F., Wagner, R.A., Wilson, K.D., Xie, X., Fu, J.D., Drukker, M., Lee, A., Li,
R.A., Gambhir, S.S., Weissman, I.L., et al. (2008). Transcriptional and func-
tional profiling of human embryonic stem cell-derived cardiomyocytes. PLoS
ONE 3, e3474.
Cao, F., Li, Z., Lee, A., Liu, Z., Chen, K., Wang, H., Cai, W., Chen, X., and Wu,
J.C. (2009). Noninvasive de novo imaging of human embryonic stem cell-
derived teratoma formation. Cancer Res. 69, 2709–2713.
Chen, I.Y., and Wu, J.C. (2011). Cardiovascular molecular imaging: focus on
clinical translation. Circulation 123, 425–443.
Chen, H.S., Kim, C., and Mercola, M. (2009). Electrophysiological challenges
of cell-based myocardial repair. Circulation 120, 2496–2508.
Christen, T., Nahrendorf, M., Wildgruber, M., Swirski, F.K., Aikawa, E.,
Waterman, P., Shimizu, K., Weissleder, R., and Libby, P. (2009). Molecular
imaging of innate immune cell function in transplant rejection. Circulation
119, 1925–1932.
Clifford, D.M., Fisher, S.A., Brunskill, S.J., Doree, C., Mathur, A., Watt, S., and
Martin-Rendon, E. (2012). Stem cell treatment for acute myocardial infarction.
Cochrane Database Syst. Rev. 2, CD006536.
Correa, P.L., Mesquita, C.T., Felix, R.M., Azevedo, J.C., Barbirato, G.B.,
Falca˜o, C.H., Gonzalez, C., Mendonc¸a, M.L., Manfrim, A., de Freitas, G.,
et al. (2007). Assessment of intra-arterial injected autologous bone marrow
mononuclear cell distribution by radioactive labeling in acute ischemic stroke.
Clin. Nucl. Med. 32, 839–841.
Daadi, M.M., Li, Z., Arac, A., Grueter, B.A., Sofilos, M., Malenka, R.C., Wu,
J.C., and Steinberg, G.K. (2009). Molecular and magnetic resonance imaging
of human embryonic stem cell-derived neural stem cell grafts in ischemic rat
brain. Mol. Ther. 17, 1282–1291.
de Almeida, P.E., Ransohoff, J.D., Nahid, A., and Wu, J.C. (2013). Immunoge-
nicity of pluripotent stem cells and their derivatives. Circ. Res. 112, 549–561.
de Vries, I.J., Lesterhuis, W.J., Barentsz, J.O., Verdijk, P., van Krieken, J.H.,
Boerman, O.C., Oyen, W.J., Bonenkamp, J.J., Boezeman, J.B., Adema,
G.J., et al. (2005). Magnetic resonance tracking of dendritic cells in melanoma
patients for monitoring of cellular therapy. Nat. Biotechnol. 23, 1407–1413.
Dedobbeleer, C., Blocklet, D., Toungouz, M., Lambermont, M., Unger, P.,
Degaute, J.P., Goldman, S., and Berkenboom, G. (2009). Myocardial homing
and coronary endothelial function after autologous blood CD34+ progenitor
cells intracoronary injection in the chronic phase of myocardial infarction.
J. Cardiovasc. Pharmacol. 53, 480–485.
Drukker,M., Katchman, H., Katz, G., Even-Tov Friedman, S., Shezen, E., Horn-
stein, E., Mandelboim, O., Reisner, Y., and Benvenisty, N. (2006). Human
embryonic stem cells and their differentiated derivatives are less susceptible
to immune rejection than adult cells. Stem Cells 24, 221–229.
Dubois, N.C., Craft, A.M., Sharma, P., Elliott, D.A., Stanley, E.G., Elefanty,
A.G., Gramolini, A., and Keller, G. (2011). SIRPA is a specific cell-surface
marker for isolating cardiomyocytes derived from human pluripotent stem
cells. Nat. Biotechnol. 29, 1011–1018.
Fadini, G.P., Agostini, C., and Avogaro, A. (2010). Autologous stem cell therapy
for peripheral arterial disease meta-analysis and systematic review of the liter-
ature. Atherosclerosis 209, 10–17.
Garber, K. (2013). Inducing translation. Nat. Biotechnol. 31, 483–486.
Garbern, J.C., and Lee, R.T. (2013). Cardiac stem cell therapy and the promise
of heart regeneration. Cell Stem Cell 12, 689–698.
Guha, P., Morgan, J.W., Mostoslavsky, G., Rodrigues, N.P., and Boyd, A.S.
(2013). Lack of immune response to differentiated cells derived from syngeneic
induced pluripotent stem cells. Cell Stem Cell 12, 407–412.Cell Stem Cell 14, April 3, 2014 ª2014 Elsevier Inc. 441
Cell Stem Cell
ReviewGutierrez-Aranda, I., Ramos-Mejia, V., Bueno, C., Munoz-Lopez, M., Real,
P.J., Ma´cia, A., Sanchez, L., Ligero, G., Garcia-Parez, J.L., and Menendez,
P. (2010). Human induced pluripotent stem cells develop teratoma more effi-
ciently and faster than human embryonic stem cells regardless the site of injec-
tion. Stem Cells 28, 1568–1570.
Guzman, R., Uchida, N., Bliss, T.M., He, D., Christopherson, K.K., Stellwagen,
D., Capela, A., Greve, J., Malenka, R.C., Moseley, M.E., et al. (2007). Long-
term monitoring of transplanted human neural stem cells in developmental
and pathological contexts with MRI. Proc. Natl. Acad. Sci. USA 104, 10211–
10216.
Gyo¨ngyo¨si, M., Blanco, J., Marian, T., Tro´n, L., Petneha´zy, O., Petrasi, Z.,
Hemetsberger, R., Rodriguez, J., Font, G., Pavo, I.J., et al. (2008). Serial nonin-
vasive in vivo positron emission tomographic tracking of percutaneously intra-
myocardially injected autologous porcine mesenchymal stem cells modified
for transgene reporter gene expression. Circ Cardiovasc Imaging 1, 94–103.
Gyo¨ngyo¨si, M., Hemetsberger, R., Wolbank, S., Kaun, C., Posa, A., Marian, T.,
Balkay, L., Emri, M., Galuska, L., Mikecz, P., et al. (2010). Imaging the migra-
tion of therapeutically delivered cardiac stem cells. JACCCardiovasc. Imaging
3, 772–775.
Hare, J.M., Fishman, J.E., Gerstenblith, G., DiFede Velazquez, D.L., Zam-
brano, J.P., Suncion, V.Y., Tracy, M., Ghersin, E., Johnston, P.V., Brinker,
J.A., et al. (2012). Comparison of allogeneic vs autologous bone marrow–
derived mesenchymal stem cells delivered by transendocardial injection in
patients with ischemic cardiomyopathy: the POSEIDON randomized trial.
JAMA 308, 2369–2379.
Heldman, A.W., DiFede, D.L., Fishman, J.E., Zambrano, J.P., Trachtenberg,
B.H., Karantalis, V., Mushtaq, M., Williams, A.R., Suncion, V.Y., McNiece,
I.K., et al. (2014). Transendocardial mesenchymal stem cells andmononuclear
bone marrow cells for ischemic cardiomyopathy: the TAC-HFT randomized
trial. JAMA 311, 62–73.
Hoehn, M., Ku¨stermann, E., Blunk, J., Wiedermann, D., Trapp, T., Wecker, S.,
Fo¨cking, M., Arnold, H., Hescheler, J., Fleischmann, B.K., et al. (2002). Moni-
toring of implanted stem cell migration in vivo: a highly resolved in vivo mag-
netic resonance imaging investigation of experimental stroke in rat. Proc.
Natl. Acad. Sci. USA 99, 16267–16272.
Hoffmann, J., Glassford, A.J., Doyle, T.C., Robbins, R.C., Schrepfer, S., and
Pelletier, M.P. (2010). Angiogenic effects despite limited cell survival of
bone marrow-derived mesenchymal stem cells under ischemia. Thorac.
Cardiovasc. Surg. 58, 136–142.
Hofmann, M., Wollert, K.C., Meyer, G.P., Menke, A., Arseniev, L., Hertenstein,
B., Ganser, A., Knapp, W.H., and Drexler, H. (2005). Monitoring of bone
marrow cell homing into the infarcted human myocardium. Circulation 111,
2198–2202.
Hou, D., Youssef, E.A., Brinton, T.J., Zhang, P., Rogers, P., Price, E.T., Yeung,
A.C., Johnstone, B.H., Yock, P.G., and March, K.L. (2005). Radiolabeled cell
distribution after intramyocardial, intracoronary, and interstitial retrograde cor-
onary venous delivery: implications for current clinical trials. Circulation Suppl.
112, I150–I156.
Huang, N.F., Niiyama, H., Peter, C., De, A., Natkunam, Y., Fleissner, F., Li, Z.,
Rollins, M.D., Wu, J.C., Gambhir, S.S., and Cooke, J.P. (2010). Embryonic
stem cell-derived endothelial cells engraft into the ischemic hindlimb and
restore perfusion. Arterioscler. Thromb. Vasc. Biol. 30, 984–991.
Huber, B.C., Ransohoff, J.D., Ransohoff, K.J., Riegler, J., Ebert, A., Kodo, K.,
Gong, Y., Sanchez-Freire, V., Dey, D., Kooreman, N.G., et al. (2013). Costimu-
lation-adhesion blockade is superior to cyclosporine A and prednisone
immunosuppressive therapy for preventing rejection of differentiated human
embryonic stem cells following transplantation. Stem Cells 31, 2354–2363.
Kang, J.H., Lee, D.S., Paeng, J.C., Lee, J.S., Kim, Y.H., Lee, Y.J., Hwang,
D.W., Jeong, J.M., Lim, S.M., Chung, J.K., and Lee, M.C. (2005). Development
of a sodium/iodide symporter (NIS)-transgenic mouse for imaging of cardio-
myocyte-specific reporter gene expression. J. Nucl. Med. 46, 479–483.
Kang, W.J., Kang, H.J., Kim, H.S., Chung, J.K., Lee, M.C., and Lee, D.S.
(2006). Tissue distribution of 18F-FDG-labeled peripheral hematopoietic
stem cells after intracoronary administration in patients with myocardial infarc-
tion. Journal of Nuclear Medicine 47, 1295–1301.
Karow, M., Chavez, C.L., Farruggio, A.P., Geisinger, J.M., Keravala, A., Jung,
W.E., Lan, F., Wu, J.C., Chen-Tsai, Y., and Calos, M.P. (2011). Site-specific re-442 Cell Stem Cell 14, April 3, 2014 ª2014 Elsevier Inc.combinase strategy to create induced pluripotent stem cells efficiently with
plasmid DNA. Stem Cells 29, 1696–1704.
Karpov, R.S., Popov, S.V., Markov, V.A., Suslova, T.E., Ryabov, V.V., Popo-
nina, Y.S., Krylov, A.L., and Sazonova, S.V. (2005). Autologous mononuclear
bone marrow cells during reparative regeneratrion after acute myocardial
infarction. Bull. Exp. Biol. Med. 140, 640–643.
Kehat, I., Khimovich, L., Caspi, O., Gepstein, A., Shofti, R., Arbel, G., Huber, I.,
Satin, J., Itskovitz-Eldor, J., and Gepstein, L. (2004). Electromechanical inte-
gration of cardiomyocytes derived from human embryonic stem cells. Nat.
Biotechnol. 22, 1282–1289.
Kim, D.E., Schellingerhout, D., Ishii, K., Shah, K., and Weissleder, R. (2004).
Imaging of stem cell recruitment to ischemic infarcts in a murine model. Stroke
35, 952–957.
Kim, J.B., Greber, B., Arau´zo-Bravo, M.J., Meyer, J., Park, K.I., Zaehres, H.,
and Scho¨ler, H.R. (2009). Direct reprogramming of human neural stem cells
by OCT4. Nature 461, 649.
Koch, C.A., Geraldes, P., and Platt, J.L. (2008). Immunosuppression by embry-
onic stem cells. Stem Cells 26, 89–98.
Kondziolka, D., Steinberg, G.K., Wechsler, L., Meltzer, C.C., Elder, E., Gebel,
J., Decesare, S., Jovin, T., Zafonte, R., Lebowitz, J., et al. (2005). Neurotrans-
plantation for patients with subcortical motor stroke: a phase 2 randomized
trial. J. Neurosurg. 103, 38–45.
Kraehenbuehl, T.P., Ferreira, L.S., Hayward, A.M., Nahrendorf, M., van der
Vlies, A.J., Vasile, E., Weissleder, R., Langer, R., and Hubbell, J.A. (2011).
Human embryonic stem cell-derived microvascular grafts for cardiac tissue
preservation after myocardial infarction. Biomaterials 32, 1102–1109.
Kraitchman, D.L., Tatsumi, M., Gilson, W.D., Ishimori, T., Kedziorek, D., Walc-
zak, P., Segars, W.P., Chen, H.H., Fritzges, D., Izbudak, I., et al. (2005).
Dynamic imaging of allogeneic mesenchymal stem cells trafficking to myocar-
dial infarction. Circulation 112, 1451–1461.
Lan, F., Liu, J., Narsinh, K.H., Hu, S., Han, L., Lee, A.S., Karow, M., Nguyen,
P.K., Nag, D., Calos, M.P., et al. (2012). Safe genetic modification of
cardiac stem cells using a site-specific integration technique. Circulation
126 (Suppl 1 ), S20–S28.
Lee, A.S., Tang, C., Cao, F., Xie, X., van der Bogt, K., Hwang, A., Connolly, A.J.,
Robbins, R.C., and Wu, J.C. (2009). Effects of cell number on teratoma forma-
tion by human embryonic stem cells. Cell Cycle 8, 2608–2612.
Lee, J.S., Hong, J.M., Moon, G.J., Lee, P.H., Ahn, Y.H., and Bang, O.Y. (2010).
A long-term follow-up study of intravenous autologousmesenchymal stem cell
transplantation in patients with ischemic stroke. Stem Cells 28, 1099–1106.
Lees, J.S., Sena, E.S., Egan, K.J., Antonic, A., Koblar, S.A., Howells, D.W., and
Macleod, M.R. (2012). Stem cell-based therapy for experimental stroke: a sys-
tematic review and meta-analysis. Int. J. Stroke 7, 582–588.
Levit, R.D., Landa´zuri, N., Phelps, E.A., Brown, M.E., Garcı´a, A.J., Davis, M.E.,
Joseph, G., Long, R., Safley, S.A., Suever, J.D., et al. (2013). Cellular encapsu-
lation enhances cardiac repair. J Am Heart Assoc 2, e000367.
Li, Z., Wu, J.C., Sheikh, A.Y., Kraft, D., Cao, F., Xie, X., Patel, M., Gambhir,
S.S., Robbins, R.C., Cooke, J.P., and Wu, J.C. (2007). Differentiation, survival,
and function of embryonic stem cell derived endothelial cells for ischemic heart
disease. Circulation Suppl. 116, I46–I54.
Li, Z., Suzuki, Y., Huang, M., Cao, F., Xie, X., Connolly, A.J., Yang, P.C., and
Wu, J.C. (2008). Comparison of reporter gene and iron particle labeling for
tracking fate of human embryonic stem cells and differentiated endothelial
cells in living subjects. Stem Cells 26, 864–873.
Li, Z., Lee, A., Huang, M., Chun, H., Chung, J., Chu, P., Hoyt, G., Yang, P.,
Rosenberg, J., Robbins, R.C., and Wu, J.C. (2009). Imaging survival and func-
tion of transplanted cardiac resident stem cells. J. Am. Coll. Cardiol. 53, 1229–
1240.
Magliocca, J.F., Held, I.K., and Odorico, J.S. (2006). Undifferentiated murine
embryonic stem cells cannot induce portal tolerance butmay possess immune
privilege secondary to reduced major histocompatibility complex antigen
expression. Stem Cells Dev. 15, 707–717.
Makkar, R.R., Smith, R.R., Cheng, K., Malliaras, K., Thomson, L.E., Berman,
D., Czer, L.S., Marba´n, L., Mendizabal, A., Johnston, P.V., et al. (2012). Intra-
coronary cardiosphere-derived cells for heart regeneration after myocardial
Cell Stem Cell
Reviewinfarction (CADUCEUS): a prospective, randomised phase 1 trial. Lancet 379,
895–904.
Maroof, A.M., Keros, S., Tyson, J.A., Ying, S.W., Ganat, Y.M., Merkle, F.T., Liu,
B., Goulburn, A., Stanley, E.G., Elefanty, A.G., et al. (2013). Directed differen-
tiation and functional maturation of cortical interneurons from human embry-
onic stem cells. Cell Stem Cell 12, 559–572.
Massoud, T.F., and Gambhir, S.S. (2003). Molecular imaging in living subjects:
seeing fundamental biological processes in a new light. Genes Dev. 17,
545–580.
Mothe, A.J., and Tator, C.H. (2012). Advances in stem cell therapy for spinal
cord injury. J. Clin. Invest. 122, 3824–3834.
Nguyen, P.K., Lan, F., Wang, Y., andWu, J.C. (2011). Imaging: guiding the clin-
ical translation of cardiac stem cell therapy. Circ. Res. 109, 962–979.
Nicholas, C.R., Chen, J., Tang, Y., Southwell, D.G., Chalmers, N., Vogt, D.,
Arnold, C.M., Chen, Y.J., Stanley, E.G., Elefanty, A.G., et al. (2013). Functional
maturation of hPSC-derived forebrain interneurons requires an extended time-
line and mimics human neural development. Cell Stem Cell 12, 573–586.
Ochiai, H., Sakamoto, N., Fujita, K., Nishikawa, M., Suzuki, K., Matsuura, S.,
Miyamoto, T., Sakuma, T., Shibata, T., and Yamamoto, T. (2012). Zinc-finger
nuclease-mediated targeted insertion of reporter genes for quantitative imag-
ing of gene expression in sea urchin embryos. Proc. Natl. Acad. Sci. USA 109,
10915–10920.
Pearl, J.I., Lee, A.S., Leveson-Gower, D.B., Sun, N., Ghosh, Z., Lan, F., Ran-
sohoff, J., Negrin, R.S., Davis, M.M., andWu, J.C. (2011). Short-term immuno-
suppression promotes engraftment of embryonic and induced pluripotent
stem cells. Cell Stem Cell 8, 309–317.
Pearl, J.I., Kean, L.S., Davis, M.M., andWu, J.C. (2012). Pluripotent stem cells:
immune to the immune system? Science Translational Medicine 4, 164ps125.
Pendharkar, A.V., Chua, J.Y., Andres, R.H., Wang, N., Gaeta, X., Wang, H., De,
A., Choi, R., Chen, S., Rutt, B.K., et al. (2010). Biodistribution of neural stem
cells after intravascular therapy for hypoxic-ischemia. Stroke 41, 2064–2070.
Perin, E.C., Willerson, J.T., Pepine, C.J., Henry, T.D., Ellis, S.G., Zhao, D.X.,
Silva, G.V., Lai, D., Thomas, J.D., Kronenberg, M.W., et al.; Cardiovascular
Cell Therapy Research Network (CCTRN) (2012). Effect of transendocardial
delivery of autologous bone marrowmononuclear cells on functional capacity,
left ventricular function, and perfusion in chronic heart failure: the FOCUS-
CCTRN trial. JAMA 307, 1717–1726.
Ponomarev, V., Doubrovin, M., Shavrin, A., Serganova, I., Beresten, T.,
Ageyeva, L., Cai, C., Balatoni, J., Alauddin, M., and Gelovani, J. (2007). A
human-derived reporter gene for noninvasive imaging in humans: mitochon-
drial thymidine kinase type 2. J. Nucl. Med. 48, 819–826.
Poole, J., Mavromatis, K., Binongo, J.N., Khan, A., Li, Q., Khayata, M., Rocco,
E., Topel, M., Zhang, X., Brown, C., et al. (2013). Effect of progenitor cell mobi-
lization with granulocyte-macrophage colony-stimulating factor in patients
with peripheral artery disease: a randomized clinical trial. JAMA 310, 2631–
2639.
Rong, Z., Wang,M., Hu, Z., Stradner, M., Zhu, S., Kong, H., Yi, H., Goldrath, A.,
Yang, Y.G., Xu, Y., and Fu, X. (2014). An effective approach to prevent immune
rejection of human ESC-derived allografts. Cell Stem Cell 14, 121–130.
Rosenblum, S., Wang, N., Smith, T.N., Pendharkar, A.V., Chua, J.Y., Birk, H.,
and Guzman, R. (2012). Timing of intra-arterial neural stem cell transplantation
after hypoxia-ischemia influences cell engraftment, survival, and differentia-
tion. Stroke 43, 1624–1631.
Rufaihah, A.J., Huang, N.F., Jame´, S., Lee, J.C., Nguyen, H.N., Byers, B., De,
A., Okogbaa, J., Rollins, M., Reijo-Pera, R., et al. (2011). Endothelial cells
derived from human iPSCS increase capillary density and improve perfusion
in a mouse model of peripheral arterial disease. Arterioscler. Thromb. Vasc.
Biol. 31, e72–e79.
Scha¨chinger, V., Aicher, A., Do¨bert, N., Ro¨ver, R., Diener, J., Fichtlscherer, S.,
Assmus, B., Seeger, F.H., Menzel, C., Brenner, W., et al. (2008). Pilot trial on
determinants of progenitor cell recruitment to the infarcted human myocar-
dium. Circulation 118, 1425–1432.
Seif-Naraghi, S.B., Singelyn, J.M., Salvatore, M.A., Osborn, K.G., Wang, J.J.,
Sampat, U., Kwan, O.L., Strachan, G.M.,Wong, J., Schup-Magoffin, P.J., et al.
(2013). Safety and efficacy of an injectable extracellular matrix hydrogel for
treating myocardial infarction. Science Translational Medicine 5, 173ra125.Sheikh, A.Y., Lin, S.A., Cao, F., Cao, Y., van der Bogt, K.E., Chu, P., Chang,
C.P., Contag, C.H., Robbins, R.C., and Wu, J.C. (2007). Molecular imaging
of bone marrow mononuclear cell homing and engraftment in ischemic
myocardium. Stem Cells 25, 2677–2684.
Shiba, Y., Fernandes, S., Zhu, W.Z., Filice, D., Muskheli, V., Kim, J., Palpant,
N.J., Gantz, J., Moyes, K.W., Reinecke, H., et al. (2012). Human ES-cell-
derived cardiomyocytes electrically couple and suppress arrhythmias in
injured hearts. Nature 489, 322–325.
Silva, S.A., Sousa, A.L., Haddad, A.F., Azevedo, J.C., Soares, V.E., Peixoto,
C.M., Soares, A.J., Issa, A.F., Felipe, L.R., Branco, R.V., et al. (2009). Autolo-
gous bone-marrow mononuclear cell transplantation after acute myocardial
infarction: comparison of two delivery techniques. Cell Transplant. 18,
343–352.
Sommer, D., Peters, A., Wirtz, T., Mai, M., Ackermann, J., Thabet, Y., Schmidt,
J., Weighardt, H., Wunderlich, F.T., Degen, J., et al. (2014). Efficient genome
engineering by targeted homologous recombination in mouse embryos using
transcription activator-like effector nucleases. Nat Commun 5, 3045.
Swijnenburg, R.J., Schrepfer, S., Cao, F., Pearl, J.I., Xie, X., Connolly, A.J.,
Robbins, R.C., and Wu, J.C. (2008a). In vivo imaging of embryonic stem cells
reveals patterns of survival and immune rejection following transplantation.
Stem Cells Dev. 17, 1023–1029.
Swijnenburg, R.J., Schrepfer, S., Govaert, J.A., Cao, F., Ransohoff, K., Sheikh,
A.Y., Haddad, M., Connolly, A.J., Davis, M.M., Robbins, R.C., and Wu, J.C.
(2008b). Immunosuppressive therapy mitigates immunological rejection of
human embryonic stem cell xenografts. Proc. Natl. Acad. Sci. USA 105,
12991–12996.
Swijnenburg, R.J., Govaert, J.A., van der Bogt, K.E., Pearl, J.I., Huang, M.,
Stein, W., Hoyt, G., Vogel, H., Contag, C.H., Robbins, R.C., and Wu, J.C.
(2010). Timing of bone marrow cell delivery has minimal effects on cell viability
and cardiac recovery after myocardial infarction. Circ Cardiovasc Imaging 3,
77–85.
Sykova, E., and Jendelova, P. (2007). In vivo tracking of stem cells in brain and
spinal cord injury. Prog. Brain Res. 161, 367–383.
Takahashi, K., Tanabe, K., Ohnuki, M., Narita, M., Ichisaka, T., Tomoda, K.,
and Yamanaka, S. (2007). Induction of pluripotent stem cells from adult human
fibroblasts by defined factors. Cell 131, 861–872.
Tang, C., Lee, A.S., Volkmer, J.P., Sahoo, D., Nag, D., Mosley, A.R., Inlay,
M.A., Ardehali, R., Chavez, S.L., Pera, R.R., et al. (2011). An antibody against
SSEA-5 glycan on human pluripotent stem cells enables removal of teratoma-
forming cells. Nat. Biotechnol. 29, 829–834.
Templin, C., Zweigerdt, R., Schwanke, K., Olmer, R., Ghadri, J.R., Emmert,
M.Y., Mu¨ller, E., Ku¨est, S.M., Cohrs, S., Schibli, R., et al. (2012). Transplanta-
tion and tracking of human-induced pluripotent stem cells in a pig model of
myocardial infarction: assessment of cell survival, engraftment, and distribu-
tion by hybrid single photon emission computed tomography/computed
tomography of sodium iodide symporter transgene expression. Circulation
126, 430–439.
Terrovitis, J., Stuber, M., Youssef, A., Preece, S., Leppo, M., Kizana, E., Scha¨r,
M., Gerstenblith, G.,Weiss, R.G., Marba´n, E., and Abraham,M.R. (2008). Mag-
netic resonance imaging overestimates ferumoxide-labeled stem cell survival
after transplantation in the heart. Circulation 117, 1555–1562.
Toma, C., Wagner, W.R., Bowry, S., Schwartz, A., and Villanueva, F. (2009).
Fate of culture-expanded mesenchymal stem cells in the microvasculature:
in vivo observations of cell kinetics. Circ. Res. 104, 398–402.
Traverse, J.H., Henry, T.D., Ellis, S.G., Pepine, C.J., Willerson, J.T., Zhao, D.X.,
Forder, J.R., Byrne, B.J., Hatzopoulos, A.K., Penn, M.S., et al.; Cardiovascular
Cell Therapy Research Network (2011). Effect of intracoronary delivery of
autologous bone marrow mononuclear cells 2 to 3 weeks following acute
myocardial infarction on left ventricular function: the LateTIME randomized
trial. JAMA 306, 2110–2119.
Traverse, J.H., Henry, T.D., Pepine, C.J., Willerson, J.T., Zhao, D.X., Ellis, S.G.,
Forder, J.R., Anderson, R.D., Hatzopoulos, A.K., Penn, M.S., et al.; Cardiovas-
cular Cell Therapy Research Network (CCTRN) (2012). Effect of the use and
timing of bone marrow mononuclear cell delivery on left ventricular function
after acute myocardial infarction: the TIME randomized trial. JAMA 308,
2380–2389.Cell Stem Cell 14, April 3, 2014 ª2014 Elsevier Inc. 443
Cell Stem Cell
ReviewUccelli, A., Laroni, A., and Freedman, M.S. (2011). Mesenchymal stem cells for
the treatment of multiple sclerosis and other neurological diseases. Lancet
Neurol. 10, 649–656.
van der Bogt, K.E., Sheikh, A.Y., Schrepfer, S., Hoyt, G., Cao, F., Ransohoff,
K.J., Swijnenburg, R.J., Pearl, J., Lee, A., Fischbein, M., et al. (2008). Compar-
ison of different adult stem cell types for treatment of myocardial ischemia.
Circulation Suppl. 118, S121–S129.
van der Spoel, T.I., Jansen of Lorkeers, S.J., Agostoni, P., van Belle, E.,
Gyo¨ngyo¨si, M., Sluijter, J.P., Cramer, M.J., Doevendans, P.A., and Chamu-
leau, S.A. (2011). Human relevance of pre-clinical studies in stem cell therapy:
systematic review and meta-analysis of large animal models of ischaemic
heart disease. Cardiovasc. Res. 91, 649–658.
Vrtovec, B., Poglajen, G., Lezaic, L., Sever, M., Socan, A., Domanovic, D.,
Cernelc, P., Torre-Amione, G., Haddad, F., and Wu, J.C. (2013). Comparison
of transendocardial and intracoronary CD34+ cell transplantation in patients
with nonischemic dilated cardiomyopathy. Circulation 128 (Suppl 1 ),
S42–S49.
Wang, Y., Zhang, W.Y., Hu, S., Lan, F., Lee, A.S., Huber, B., Lisowski, L.,
Liang, P., Huang, M., de Almeida, P.E., et al. (2012). Genome editing of human
embryonic stem cells and induced pluripotent stem cells with zinc finger nucle-
ases for cellular imaging. Circ. Res. 111, 1494–1503.
Wernig, M., Benninger, F., Schmandt, T., Rade, M., Tucker, K.L., Bu¨ssow, H.,
Beck, H., and Bru¨stle, O. (2004). Functional integration of embryonic stem cell-
derived neurons in vivo. J. Neurosci. 24, 5258–5268.444 Cell Stem Cell 14, April 3, 2014 ª2014 Elsevier Inc.Xie, X., Chan, K.S., Cao, F., Huang, M., Li, Z., Lee, A., Weissman, I.L., and Wu,
J.C. (2009). Imaging of STAT3 signaling pathway during mouse embryonic
stem cell differentiation. Stem Cells Dev. 18, 205–214.
Yaghoubi, S.S., Jensen, M.C., Satyamurthy, N., Budhiraja, S., Paik, D.,
Czernin, J., and Gambhir, S.S. (2009). Noninvasive detection of therapeutic
cytolytic T cells with 18F-FHBG PET in a patient with glioma. Nat. Clin. Pract.
Oncol. 6, 53–58.
Yang, H., Wang, H., Shivalila, C.S., Cheng, A.W., Shi, L., and Jaenisch,
R. (2013). One-step generation of mice carrying reporter and conditional
alleles by CRISPR/Cas-mediated genome engineering. Cell 154, 1370–
1379.
Yilmaz, A., Ro¨sch, S., Klingel, K., Kandolf, R., Helluy, X., Hiller, K.H., Jakob,
P.M., and Sechtem, U. (2013). Magnetic resonance imaging (MRI) of inflamed
myocardium using iron oxide nanoparticles in patients with acute myocardial
infarction - preliminary results. Int. J. Cardiol. 163, 175–182.
Yu, J., Vodyanik, M.A., Smuga-Otto, K., Antosiewicz-Bourget, J., Frane, J.L.,
Tian, S., Nie, J., Jonsdottir, G.A., Ruotti, V., Stewart, R., et al. (2007). Induced
pluripotent stem cell lines derived from human somatic cells. Science 318,
1917–1920.
Yu, D.X., Marchetto, M.C., and Gage, F.H. (2013). Therapeutic translation of
iPSCs for treating neurological disease. Cell Stem Cell 12, 678–688.
Zhao, T., Zhang, Z.N., Rong, Z., and Xu, Y. (2011). Immunogenicity of induced
pluripotent stem cells. Nature 474, 212–215.
Zhu, J., Zhou, L., and XingWu, F. (2006). Tracking neural stem cells in patients
with brain trauma. N. Engl. J. Med. 355, 2376–2378.
